{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AC2993+%28exenatide%29&page=5",
    "query": {
      "intervention": "AC2993 (exenatide)",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 184,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AC2993+%28exenatide%29&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AC2993+%28exenatide%29&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T03:55:50.149Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00753896",
      "title": "Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2008-10",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2015-04-21",
      "last_synced_at": "2026-10-11T03:55:50.149Z",
      "location_count": 11,
      "location_summary": "Mesa, Arizona • Tempe, Arizona • Concord, California + 8 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00753896"
    },
    {
      "nct_id": "NCT01524705",
      "title": "FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Prandial insulin",
          "type": "DRUG"
        },
        {
          "name": "Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 102,
      "start_date": "2012-08",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-10-11T03:55:50.149Z",
      "location_count": 12,
      "location_summary": "San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01524705"
    },
    {
      "nct_id": "NCT01076842",
      "title": "Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin-Levemir",
          "type": "DRUG"
        },
        {
          "name": "Exenatide-Bayetta",
          "type": "DRUG"
        },
        {
          "name": "Insulin-Levemir and Exenatide-Bayetta",
          "type": "DRUG"
        },
        {
          "name": "SenseWear Pro3® armband",
          "type": "DEVICE"
        },
        {
          "name": "DexCom CGM",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 75,
      "start_date": "2008-04",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2011-06-27",
      "last_synced_at": "2026-10-11T03:55:50.149Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01076842"
    },
    {
      "nct_id": "NCT05161429",
      "title": "BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "DPP4",
          "type": "DRUG"
        },
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "Basal Insulin",
          "type": "DRUG"
        },
        {
          "name": "SLGT2",
          "type": "DRUG"
        },
        {
          "name": "SU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 550000,
      "start_date": "2021-07-01",
      "completion_date": "2024-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-11T03:55:50.149Z",
      "location_count": 5,
      "location_summary": "Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Beachwood",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05161429"
    },
    {
      "nct_id": "NCT03492580",
      "title": "A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dipeptidyl Peptidase-4 (DPP-4) Inhibitors",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-like Peptide-1 (GLP-1) Agonist",
          "type": "DRUG"
        },
        {
          "name": "Anti-hyperglycemic Agents (AHA)",
          "type": "DRUG"
        },
        {
          "name": "Thiazolidinediones (TZD)",
          "type": "DRUG"
        },
        {
          "name": "Sulfonylureas (SU)",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 714582,
      "start_date": "2018-02-22",
      "completion_date": "2018-06-25",
      "has_results": false,
      "last_update_posted_date": "2025-06-25",
      "last_synced_at": "2026-10-11T03:55:50.149Z",
      "location_count": 1,
      "location_summary": "Titusville, New Jersey",
      "locations": [
        {
          "city": "Titusville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03492580"
    },
    {
      "nct_id": "NCT02417142",
      "title": "Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2014-09",
      "completion_date": "2020-07",
      "has_results": true,
      "last_update_posted_date": "2022-01-14",
      "last_synced_at": "2026-10-11T03:55:50.149Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02417142"
    },
    {
      "nct_id": "NCT02162550",
      "title": "Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Bydureon",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phoenix VA Health Care System",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 148,
      "start_date": "2014-06",
      "completion_date": "2019-09",
      "has_results": false,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-10-11T03:55:50.149Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02162550"
    },
    {
      "nct_id": "NCT01843127",
      "title": "A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Ranolazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2013-04",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2014-03-31",
      "last_synced_at": "2026-10-11T03:55:50.149Z",
      "location_count": 3,
      "location_summary": "Chula Vista, California • Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01843127"
    },
    {
      "nct_id": "NCT02975297",
      "title": "Exenatide Once Weekly for Smoking Cessation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "NRT",
          "type": "DRUG"
        },
        {
          "name": "Counseling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 84,
      "start_date": "2016-07",
      "completion_date": "2020-01-03",
      "has_results": true,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-10-11T03:55:50.149Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02975297"
    },
    {
      "nct_id": "NCT01951651",
      "title": "Effect of Exenatide on Liver and Heart Fat and Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Glipizide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-04",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2016-05-16",
      "last_synced_at": "2026-10-11T03:55:50.149Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01951651"
    }
  ]
}